AstraZeneca (AZN) – aksjekurser og nyheter

Symboler Symboler	Pris	Endring	Endring (%)	Trend	Forrige pris ved stengetid	Åpne	Høy	Lav	Volum	Markedsverdi
SIXB Materials SIXB Materials	SIXB +0,25%	1 104,10	+2,73	+0,25%	—	1 101,37	1 103,63	1 105,31	1 091,41	—	—
SIXC Communications SIXC Communications	SIXC −1,50%	604,16	−9,19	−1,50%	—	613,35	613,35	613,35	601,49	—	—
SIXE Energy SIXE Energy	SIXE −0,09%	1 197,81	−1,02	−0,09%	—	1 198,83	1 199,68	1 199,75	1 182,41	—	—
SIXI Industrials SIXI Industrials	SIXI −0,88%	1 740,41	−15,54	−0,88%	—	1 755,95	1 754,06	1 756,03	1 734,69	—	—
SIXM Financials SIXM Financials	SIXM −0,64%	634,44	−4,07	−0,64%	—	638,51	637,41	637,41	633,05	—	—
SIXR Staples SIXR Staples	SIXR −0,31%	840,90	−2,62	−0,31%	—	843,52	843,35	846,40	837,93	—	—
SIXRE Real estate SIXRE Real estate	SIXRE −0,38%	215,13	−0,82	−0,38%	—	215,95	215,95	216,84	215,06	—	—
SIXT Technology SIXT Technology	SIXT +2,86%	3 228,71	+89,80	+2,86%	—	3 138,91	3 189,30	3 230,85	3 174,76	—	—
SIXU Utilities SIXU Utilities	SIXU +0,16%	935,87	+1,50	+0,16%	—	934,37	934,72	938,26	927,50	—	—
SIXV Health care SIXV Health care	SIXV −1,37%	1 457,12	−20,31	−1,37%	—	1 477,43	1 474,12	1 474,12	1 451,80	—	—
SIXY Discretionary SIXY Discretionary	SIXY +0,83%	2 399,84	+19,65	+0,83%	—	2 380,19	2 389,34	2 403,04	2 380,47	—	—

AZN:LON

AstraZeneca

13 964,00 GBX

+0,06%

(+8,00) 1 D

27. apr., 13:01:25 GMT+1 · GBX

Alle symboler

1 D

5 D

1 M

6 M

I år

1 Å

5 Å

MAKS

	Symbol	Pris	Endring	Endring (%)

Genererer viktig statistikk for AZN …

Åpne

14 026,00 GBX

Høy

14 060,00 GBX

Lav

13 950,00 GBX

Markedsverdi

215,55 mrd.

Snittvolum

2,19 mill.

Volum

341,46k

Utbytte

1,69 %

Kvartalsvis utbytte

59,05 GBX

Første dato etter utbytte

19. feb. 2026

P/E-forhold

28,86

52 u høy

15 732,00 GBX

52 u lav

9 651,00 GBX

EPS

4,84 GBX

Utestående aksjer

1,55 mrd.

Antall ansatte

96k

Relaterte aksjer

Nyhetssaker

Fra kilder på nettet

Investing.com

for 24 minutter siden

FDA approves AstraZeneca’s Saphnelo autoinjector for lupus

TipRanks

for 56 minutter siden

AstraZeneca Stock ($AZN) Flattens Despite Green Light for Injector Pen to Stop “Killer” Lupus

Stock Titan

for 1 time siden

Lupus patients can now self-inject AstraZeneca drug in the US

London South East

for 4 timer siden

AstraZeneca says lupus treatment gets US FDA approval

Profil

AstraZeneca plc is a Swedish–British multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, UK. It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation. The company was founded in 1999 through the merger of the Swedish Astra AB and the British Zeneca Group. Zeneca shareholders received 53.5% of the shares, while Astra shareholders received the remaining 46.5%. Its portfolio includes primary and speciality care, coverage for rare diseases, and a robust global presence across various regions. Since the merger it has been among the world's largest pharmaceutical companies and has made numerous corporate acquisitions, including Cambridge Antibody Technology, MedImmune, Spirogen and Definiens. It has its research and development concentrated in three strategic centres: Cambridge, UK; Gothenburg, Sweden; and Gaithersburg, Maryland, US. AstraZeneca traces its earliest corporate history to 1913, when Astra AB was formed by a large group of doctors and apothecaries in Södertälje. Wikipedia

Om AstraZeneca

Administrerende direktørPascal Soriot

Ansatte96,1k

Grunnlagt6. apr. 1999

HovedkontorCambridge, Cambridgeshire, Storbritannia

Sektor-

Nettstedastrazeneca.com

Alle verdier i USD	mars 2025	juni 2025	sep. 2025	des. 2025
Inntekt	13,59 mrd.	14,46 mrd.	15,19 mrd.	15,50 mrd.
Varekostnad	2,23 mrd.	2,55 mrd.	2,79 mrd.	3,17 mrd.
Direkte driftskostnader	2,23 mrd.	2,55 mrd.	2,79 mrd.	3,17 mrd.
Utgifter til forskning og utvikling	3,10 mrd.	3,51 mrd.	3,63 mrd.	3,62 mrd.
Totale kostnader til forskning og utvikling	-	-	-	-
Salgskostnader, generelle kostnader og administrative kostnader	4,57 mrd.	4,98 mrd.	5,20 mrd.	5,32 mrd.
Driftskostnader	7,56 mrd.	8,42 mrd.	8,74 mrd.	8,99 mrd.
Totale driftskostnader	9,79 mrd.	10,97 mrd.	11,53 mrd.	12,16 mrd.
Driftsinntekter	3,80 mrd.	3,49 mrd.	3,66 mrd.	3,35 mrd.
Andre ikke-operasjonelle inntekter	-	-	-	−247,00 mill.
EBT inkludert uvanlige elementer	3,40 mrd.	3,13 mrd.	3,24 mrd.	2,63 mrd.
EBT uten uvanlige elementer	3,52 mrd.	3,11 mrd.	3,32 mrd.	3,05 mrd.
Kostnad for inntektsskatt	481,00 mill.	679,00 mill.	709,00 mill.	300,00 mill.
Faktisk avgiftssats	14,14 %	21,71 %	21,86 %	11,41 %
Andre driftskostnader	−114,00 mill.	−72,00 mill.	−89,00 mill.	53,00 mill.
Nettoinntekt	2,92 mrd.	2,45 mrd.	2,53 mrd.	2,33 mrd.
Netto fortjenestemargin	21,46 %	16,95 %	16,67 %	15,00 %
Resultat per aksje	2,49	2,17	2,38	2,12
Rente- og investeringsinntekter	84,00 mill.	65,00 mill.	85,00 mill.	135,00 mill.
Rentekostnader	−349,00 mill.	−436,00 mill.	−434,00 mill.	−155,00 mill.
Netto rentekostnader	−265,00 mill.	−371,00 mill.	−349,00 mill.	−20,00 mill.
Avskrivnings- og amortiseringskostnader	-	-	-	-
EBITDA	5,08 mrd.	4,88 mrd.	5,21 mrd.	4,11 mrd.
Gevinst eller tap ved salg av eiendeler	−66,00 mill.	−21,00 mill.	−31,00 mill.	−37,00 mill.

AI-innhold kan inneholde feil. Finn ut mer

HjelpSend tilbakemeldingPersonvern Vilkår Ansvarsfraskrivelse

Finance

Utforskning